Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predicting Stroke Risk in ICAD With Novel MRI Techniques
NCT05515874Phase 4Withdrawn
- Sponsor
- Northwestern University
- Start
- Sep 2020
- Primary completion
- Jun 2025
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ferumoxytol in intracranial atherosclerosis (ICAD), sponsored by Northwestern University. Planned start Sep 2020; status: withdrawn.
02
Drugs
ferumoxytol
03
Conditions
intracranial atherosclerosis (ICAD)
Beyond the preview
Go deeper on NCT05515874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515874.